Completed PHASE2/PHASE3 INTERVENTIONAL 3-arm NCT01171014

Effect of Bifidobacterium Lactis HN019 on Colonic Transit Time and Digestive Symptoms

A Three-Arm, Placebo Controlled, Double-Blind, Single Center Study to Evaluate the Impact of Probiotic Strain Bifidobacterium Lactis HN019 on Intestinal Well-Being, Colonic Transit Time and Digestive Discomfort

Sponsor: Danisco

Conditions Gastrointestinal Symptoms

Interventions Bifidobacterium lactis HN019 Placebo

Updated 6 times since 2017 Last updated: Jul 27, 2010 Started: Jun 30, 2009 Primary completion: Dec 31, 2009 Completion: Dec 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2/PHASE3 trial investigates Gastrointestinal Symptoms and is currently completed. Danisco leads this study, which shows 6 recorded versions since 2009 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Sep 2020 — Jan 2021 [monthly]

Completed PHASE2_PHASE3
Jun 2018 — Sep 2020 [monthly]

Completed PHASE2_PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2_PHASE3

First recorded

Jun 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Danisco
Fonterra Research Centre
Sprim Advanced Life Sciences

Data source: Fonterra Research Centre

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.